Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (Q33380148)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. |
scientific article |
Statements
1 reference
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (English)
1 reference
Clara D Bloomfield
1 reference
Krzysztof Mrózek
1 reference
Michael A Caligiuri
1 reference
Jonathan E Kolitz
1 reference
Bayard L Powell
1 reference
Ben L Sanford
1 reference
John Anastasi
1 reference
Maria R Baer
1 reference
Stephen L George
1 reference
Sandra M Bothun
1 reference
Joseph O Moore
1 reference
Richard M Stone
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference